title: Efficacy of OKT3 retreatment for refractory cardiac allograft rejection.
abstract: Although OKT3 monoclonal antibody is a useful therapy for refractory cardiac allograft rejection, the use of OKT3 for prophylaxis may be limited by the potential of sensitization and subsequent loss of efficacy on retreatment. OKT3 was required for refractory rejection in 21 of 165 recipients transplanted between March 1985 and August 1988. Twelve of these patients had previously been exposed to OKT3, and the retreatment efficacy was evaluated. The study population averaged 42.1 +/- 15.3 years of age (mean +/- SEM) and had experienced 2 +/- 1 previous episodes of rejection. The prior episodes of rejection had been treated with pulse methylprednisolone and antithymocyte globulin, and in addition 3 patients (25%) also required a course of antilymphoblast globulin. Retreatment OKT3 for refractory rejection was required 120 +/- 94 days following transplantation. CD3+ lymphocytes were eliminated from the circulation within 24-48 hr in 11 of 12 patients, all of whom showed histologic improvement within the first week. Total resolution on the initial follow-up biopsy was noted in 9 (75%) during the course of therapy. Subsequent rejection episodes occurred in 9 (82%) of the survivors at 71 +/- 64 days. One-year survival was 83% in this vigorously rejecting patient population. Serious infections occurred within 3 months of therapy in 4 (36%). The side effects of OKT3 retreatment were similar to those seen with first exposure and did not require OKT3 discontinuation. Thus OKT3 may be administered with success in most patients who have previously been exposed to it.
authors.affiliation: Utah Transplantation Affiliated Hospitals (UTAH), Cardiac Transplant Program, Salt Lake City 84132.
authors.forename: J B
authors.initials: JB
authors.lastname: O'Connell
authors.forename: D G
authors.initials: DG
authors.lastname: Renlund
authors.forename: W A
authors.initials: WA
authors.lastname: Gay
authors.forename: C W
authors.initials: CW
authors.lastname: DeWitt
authors.forename: E H
authors.initials: EH
authors.lastname: Hammond
authors.forename: R L
authors.initials: RL
authors.lastname: Yowell
authors.forename: K W
authors.initials: KW
authors.lastname: Jones
authors.forename: S V
authors.initials: SV
authors.lastname: Karwande
authors.forename: D B
authors.initials: DB
authors.lastname: Doty
authors.forename: M R
authors.initials: MR
authors.lastname: Bristow
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006084:Graft Rejection; D016027:Heart Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D013601:T-Lymphocytes / Q000276:immunology; D014184:Transplantation, Homologous
chemical_list: D000911:Antibodies, Monoclonal